By Staff Reporter
THE drug Exjade used in the treatment of thalassaemia has already been bought and it’s only a matter of time until patients receive it, according to the tenders board.
The board was responding yesterday to accusations made by the Cyprus Thalassaemia Association (CTA) on Wednesday. The CTA issued a statement accusing the state of dragging its feet when it came to approving the administration of Exjade to thalassemia patients.
Exjade’s main use is to reduce chronic iron overload in patients who receive long-term blood transfusions for conditions such as thalassaemia and other chronic anaemia conditions. It is marketed in Cyprus by Novartis.
“We gave approval to buy the drug on June 5, at a total cost of €4.8 million. The drug has been acquired but until its time to be administered to patients, the health ministry has enough supply stored,” said a statement from the board.
The CTA had also accused the state of unnecessary bureaucracy, pointing out that recipients of the drugs had to be tested three times in the span of one year.
The Board assured CTA that the matter would be resolved shortly.